SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.9B
Q1 2021
Positions
85
Filings on Record
27
2019–present window
Filed
May 17, 2021
original filing

Summary

Boxer Capital, LLC reported $2.9B in U.S.-listed holdings across 85 positions for Q1 2021.

Its largest position, MRTXEUR, represents 11.6% of the portfolio.

Compared with Q4 2020, the fund opened 16 new positions and exited 9.

Portfolio Metrics

Turnover
+15.3%
vs prior filed quarter
Top-10 Concentration
+48.3%
share of reported value
Largest Position
+11.6%
Mirati Therapeutics
New / Exited
16 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 72.8%Other: 13.9%ADR: 12.4%ETP: 0.9%Equity WRT: 0.0%
  • Common Stock · 72.8% · $2.1B
  • Other · 13.9% · $409M
  • ADR · 12.4% · $366M
  • ETP · 0.9% · $27M
  • Equity WRT · 0.0% · $712,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SGENUSDSEAGEN INCNEW+400.0K400.0K+$56M$56M
NUVBNUVATION BIO INCNEW+4.34M4.34M+$45M$45M
CGEMCULLINAN ONCOLOGY INCNEW+1.07M1.07M+$45M$45M
CONNECT BIOPHARMA HLDS LTDNEW+2.08M2.08M+$39M$39M
698ACHILLES THERAPEUTICS PLCNEW+1.54M1.54M+$25M$25M
EPIEURESSA PHARMA INCNEW+687.0K687.0K+$20M$20M
TALIS BIOMEDICAL CORPNEW+1.55M1.55M+$20M$20M
GEMINI THERAPEUTICS INCNEW+1.30M1.30M+$18M$18M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM11.62%$343M2.00M
2ONCBEIGENE LTDhistory →SPONSORED ADR9.02%$266M764.2K
3RVMDREVOLUTION MEDICINES INChistory →COM5.42%$160M3.48M
4SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM5.18%$153M2.08M
52662247DITEOS THERAPEUTICS INChistory →COM5.04%$149M4.35M
6SG7SAGE THERAPEUTICS INChistory →COM2.78%$82M1.09M
7PMVPPMV PHARMACEUTICALS INChistory →COM2.53%$75M2.27M
8SPRYSILVERBACK THERAPEUTICS INChistory →COM2.48%$73M1.68M
9RCKTROCKET PHARMACEUTICALS INChistory →COM2.21%$65M1.47M
10RCUSARCUS BIOSCIENCES INChistory →COM1.99%$59M2.08M
11SGENUSDSEAGEN INChistory →COM1.88%$56M400.0K
12IDYAIDEAYA BIOSCIENCES INChistory →COM1.76%$52M2.20M
13SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.73%$51M2.29M
14BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM1.66%$49M2.01M
15CYTKCYTOKINETICS INChistory →COM NEW1.66%$49M2.10M
16ARGXARGENX SEhistory →SPONSORED ADR1.60%$47M170.9K
17NUVBNUVATION BIO INChistory →COM CL A1.54%$45M4.34M
18CGEMCULLINAN ONCOLOGY INChistory →COM1.52%$45M1.07M
19RLAYRELAY THERAPEUTICS INChistory →COM1.52%$45M1.29M
20DBV TECHNOLOGIES S ASPONSORED ADR1.36%$40M7.53M
21MERUS N VCOM1.35%$40M1.90M
22CONNECT BIOPHARMA HLDS LTDADS1.31%$39M2.08M
23NRIXNURIX THERAPEUTICS INChistory →COM1.29%$38M1.22M
24AMARIN CORP PLCSPONS ADR NEW1.26%$37M6.00M
25MARINUS PHARMACEUTICALS INCCOM NEW1.26%$37M2.40M
26BCABGBPBIOATLA INChistory →COM1.18%$35M686.3K
27ALIGOS THERAPEUTICS INCCOM1.18%$35M1.53M
28ATRECA INCCL A COM1.15%$34M2.20M
29PASSAGE BIO INCCOM1.14%$34M1.93M
30KNTEUSDKINNATE BIOPHARMA INChistory →COM1.13%$33M1.07M
31KURAKURA ONCOLOGY INChistory →COM1.01%$30M1.05M
32ANABANAPTYSBIO INChistory →COM0.95%$28M1.30M
33DIREXION SHS ETF TRDAILY S&P BIOTEC0.92%$27M1.25M
34698ACHILLES THERAPEUTICS PLChistory →SPONSORED ADS0.86%$25M1.54M
35RNAGBPAVIDITY BIOSCIENCES INChistory →COM0.83%$24M1.12M
36KDMNKADMON HLDGS INChistory →COM0.82%$24M6.21M
37AKROAKERO THERAPEUTICS INChistory →COM0.82%$24M831.5K
38GOSSGOSSAMER BIO INChistory →COM0.80%$24M2.56M
39SOLID BIOSCIENCES INCCOM0.79%$23M4.23M
40AM6AMICUS THERAPEUTICS INChistory →COM0.78%$23M2.33M
41MREOMEREO BIOPHARMA GROUP PLChistory →ADS0.71%$21M6.23M
42EPIEURESSA PHARMA INChistory →COM NEW0.68%$20M687.0K
43TALIS BIOMEDICAL CORPCOM0.68%$20M1.55M
44ODONATE THERAPEUTICS INCCOM0.65%$19M5.61M
45BMRNBIOMARIN PHARMACEUTICAL INChistory →COM0.64%$19M250.0K
46NEOLEUKIN THERAPEUTICS INCCOM0.63%$18M1.50M
47CYMABAY THERAPEUTICS INCCOM0.62%$18M4.00M
48CABACABALETTA BIO INChistory →COM0.60%$18M1.60M
49GEMINI THERAPEUTICS INCCOM0.60%$18M1.30M
50IMVTIMMUNOVANT INChistory →COM0.54%$16M1.00M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.